Der Gynäkologe

, Volume 43, Issue 7, pp 595–600

Angiogenese in Reproduktionsmedizin und gynäkologischer Onkologie

Leitthema
  • 50 Downloads

Zusammenfassung

Angiogenese bezeichnet das Wachstum von Blutgefäßen aus einem vorgebildeten Kapillarsystem. Angiogenese ist ein physiologischer Prozess bei Entwicklung und Wachstum von Geweben und Organen. Die Blutgefäßentwicklung wird durch eine Veränderung des Gleichgewichts zwischen pro- und antiangiogenen Faktoren induziert. Angiogenese spielt in der Kontrolle des Menstruationszyklus sowie bei Implantation und Wachstum der Plazenta eine wichtige Rolle. Bei vielen Erkrankungen in der Gynäkologie und Geburtshilfe (z. B. ovarielles Hyperstimulationssyndrom, Endometriose, Präeklampsie) ist die Regulation angiogener Prozesse gestört. Angiogenese ist auch beim Wachstum und der Metastasierung maligner Tumoren von essentieller Bedeutung. Inhibitoren der Tumorangiogenese sind in den Blickpunkt neuer Therapiestrategien gekommen. Die Wirksamkeit des antiangiogenen Antikörpers Bevacizumab in der Behandlung von metastasierendem Brustkrebs wurde nachgewiesen. Der Beitrag gibt eine Übersicht über die Rolle der Angiogenese in der Reproduktionsmedizin und der gynäkologischen Onkologie mit Akzentuierung der klinischen Relevanz.

Schlüsselwörter

Angiogenese Antiangiogenese Menstruationszyklus Plazentation Gynäkologische Tumoren 

Angiogenesis in reproduction medicine and gynecological oncolology

Abstract

Angiogenesis is a physiological process involving the growth of new blood vessels from pre-existing vessels. The formation of new blood vessels is a normal and vital process in growth and development. The switch to the angiogenic phenotype is induced by a change in the balance of positive and negative regulators of angiogenesis. Angiogenesis plays an important role in the regulation of the female menstrual cycle. In prenatal medicine the formation of blood vessels is also significant for implantation and for the development of the placenta. The regulation of angiogenetic processes is defective in many gynecological and obstetric diseases (e.g. ovarian hyperstimulation syndrome, endometriosis and preeclampsia). Angiogenesis also plays an important role in the growth and metastasization of malignant tumors. Inhibition of tumor angiogenesis has become the focus of new treatment strategies. The efficacy of the anti-angiogenic antibody bevacizumab in the treatment of metastatic breast cancer has been demonstrated. This article gives an overview of the role of angiogenesis in the female reproductive system and in gynecological oncology with the main focus on the clinical significance.

Keywords

Angiogenesis Anti-angiogenesis Menstrual cycle Placentation Gynecological tumors 

Literatur

  1. 1.
    Auguste P, Javerzat S, Bikfalvi A (2003) Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 314:157–166CrossRefPubMedGoogle Scholar
  2. 2.
    Augustin HG, Braun K, Telemenakis I et al (1995) Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am J Pathol 147:339–351PubMedGoogle Scholar
  3. 3.
    Becker CM, D’Amato RJ (2007) Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 74:121–130CrossRefPubMedGoogle Scholar
  4. 4.
    Burger RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25:2902–2908CrossRefPubMedGoogle Scholar
  5. 5.
    Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–5186CrossRefPubMedGoogle Scholar
  6. 6.
    Cao Y (2001) Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 33:357–369CrossRefPubMedGoogle Scholar
  7. 7.
    Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932–936CrossRefPubMedGoogle Scholar
  8. 8.
    Davis S, Yancopoulos GD (1999) The angiopoietins: Yin and Yang in angiogenesis. Curr Top Microbiol Immunol 237:173–185PubMedGoogle Scholar
  9. 9.
    Eberhard A, Kahlert S, Goede V et al (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388–1393PubMedGoogle Scholar
  10. 10.
    Ferrara N, Chen H, Davis-Smyth T et al (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4:336–340CrossRefPubMedGoogle Scholar
  11. 11.
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedGoogle Scholar
  12. 12.
    Fraser HM, Wulff C (2003) Angiogenesis in the corpus luteum. Reprod Biol Endocrinol 1:88CrossRefPubMedGoogle Scholar
  13. 13.
    Geva E, Jaffe RB (2000) Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 74:429–438CrossRefPubMedGoogle Scholar
  14. 14.
    Gomez-Raposo C, Mendiola M, Barriuso J et al (2009) Angiogenesis and ovarian cancer. Clin Transl Oncol 11:564–571CrossRefPubMedGoogle Scholar
  15. 15.
    Gordon JD, Shifren JL, Foulk RA et al (1995) Angiogenesis in the human female reproductive tract. Obstet Gynecol Surv 50:688–697CrossRefPubMedGoogle Scholar
  16. 16.
    Hamilton CA, Maxwell GL, Chernofsky MR et al (2008) Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111:530–532CrossRefPubMedGoogle Scholar
  17. 17.
    Hawighorst T, Hussein F, Stein W et al (2008) Anti-angiogenesis: Moving from preclinical research to clinical application. Geburtshilfe Frauenheilkd 68:397–403CrossRefGoogle Scholar
  18. 18.
    Hawighorst T, Oura H, Streit M et al (2002) Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene 21:7945–7956CrossRefPubMedGoogle Scholar
  19. 19.
    Hawighorst T, Velasco P, Streit M et al (2001) Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 20:2631–2640CrossRefPubMedGoogle Scholar
  20. 20.
    Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149–153CrossRefPubMedGoogle Scholar
  21. 21.
    Jaffe RB (2000) Importance of angiogenesis in reproductive physiology. Semin Perinatol 24:79–81CrossRefPubMedGoogle Scholar
  22. 22.
    Kamat AA, Merritt WM, Coffey D et al (2007) Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13:7487–7495CrossRefPubMedGoogle Scholar
  23. 23.
    Khosravi Shahi P, Soria Lovelle A, Perez Manga G (2009) Tumoral angiogenesis and breast cancer. Clin Transl Oncol 11:138–142CrossRefGoogle Scholar
  24. 24.
    Lawler J, Detmar M (2004) Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 36:1038–1045CrossRefPubMedGoogle Scholar
  25. 25.
    Levine RJ, Maynard SE, Qian C et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683CrossRefPubMedGoogle Scholar
  26. 26.
    Loges S, Mazzone M, Hohensinner P, Carmeliet P (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15:167–170CrossRefPubMedGoogle Scholar
  27. 27.
    Maynard SE, Min JY, Merchan J et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia. J Clin Invest 111:649–658PubMedGoogle Scholar
  28. 28.
    Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676CrossRefPubMedGoogle Scholar
  29. 29.
    Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10:165–180CrossRefPubMedGoogle Scholar
  30. 30.
    Reynolds LP, Borowicz PP, Caton JS et al (n d) Uteroplacental vascular development and placental function: an update. Int J Dev Biol 54:355–366Google Scholar
  31. 31.
    Roberts JM, Taylor RN, Musci TJ et al (1989) Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161:1200–1204PubMedGoogle Scholar
  32. 32.
    Selvaggi L, Ribatti D, Loverro G et al (1995) Angiogenesis in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 59:83–89CrossRefPubMedGoogle Scholar
  33. 33.
    Senger DR, Connolly DT, Van de Water L et al (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774–1778PubMedGoogle Scholar
  34. 34.
    Shokry M, Bedaiwy MA, Fathalla MM et al (2010) Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Acta Obstet Gynecol Scand 89:143–146CrossRefPubMedGoogle Scholar
  35. 35.
    Torry DS, Holt VJ, Keenan JA et al (1996) Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril 66:72–80PubMedGoogle Scholar
  36. 36.
    Tsampalas M, Gridelet V, Berndt S et al (2010) Human chorionic gonadotropin: A hormone with immunological and angiogenic properties. J Reprod ImmunolGoogle Scholar
  37. 37.
    Verlohren S, Galindo A, Schlembach D et al (2010) An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202:161 e161–161 e111CrossRefPubMedGoogle Scholar
  38. 38.
    Wang A, Rana S, Karumanchi SA (2009) Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 24:147–158Google Scholar
  39. 39.
    Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • T. Hawighorst
    • 1
  • W. Stein
    • 1
  • C. Gründker
    • 1
  • G. Emons
    • 1
  1. 1.Klinik für Gynäkologie und GeburtshilfeUniversitätsmedizin, Georg-August-Universität GöttingenGöttingenDeutschland

Personalised recommendations